Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholate for the primary treatment of invasive candidiasis. METHODS: We enrolled patients who had clinical evidence of infection and a positive culture for candida species from blood or another site. Patients were stratified according to the severity of disease, as indicated by the Acute Physiology and Chronic Health Evaluation (APACHE II) score, and the presence or absence of neutropenia and were randomly assigned to receive either caspofungin or amphotericin B. The study was designed to compare the efficacy of caspofungin with that of amphotericin B in patients with invasive candidiasis and in a subgroup with candidemia. RESULTS: Of the 239 patients enrolled, 224 were included in the modified intention-to-treat analysis. Base-line characteristics, including the percentage of patients with neutropenia and the mean APACHE II score, were similar in the two treatment groups. A modified intention-to-treat analysis showed that the efficacy of caspofungin was similar to that of amphotericin B, with successful outcomes in 73.4 percent of the patients treated with caspofungin and in 61.7 percent of those treated with amphotericin B (difference after adjustment for APACHE II score and neutropenic status, 12.7 percentage points; 95.6 percent confidence interval, -0.7 to 26.0). An analysis of patients who met prespecified criteria for evaluation showed that caspofungin was superior, with a favorable response in 80.7 percent of patients, as compared with 64.9 percent of those who received amphotericin B (difference, 15.4 percentage points; 95.6 percent confidence interval, 1.1 to 29.7). Caspofungin was as effective as amphotericin B in patients who had candidemia, with a favorable response in 71.7 percent and 62.8 percent of patients, respectively (difference, 10.0 percentage points; 95.0 percent confidence interval, -4.5 to 24.5). There were significantly fewer drug-related adverse events in the caspofungin group than in the amphotericin B group. CONCLUSIONS: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For invasive candidiasis, echinocandins were a great development that lowered the mortality associated with these infections, with low toxicity and few interactions with other medication (Mora-Duarte et al., 2002; Pappas et al., 2016).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Mora-Duarte et al., 2002
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Nguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C. E., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Self-citationVillanueva, A., Gotuzzo, E., Arathoon, E. G., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J., & Sable, C. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01191-9 · Cited by 292
Self-citation
Research works printed but not linked: 4
- Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis, and treatment. 2nd ed. New York: Raven Press, 1992:279-329.
- Yamamura DL, 1999, CMAJ, 160, 493
- Bachman SP, Pera S, Kirkpatrick WR, Patterson TF, Lopez-Ribot JL. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000. Washington, D.C.: American Society for Microbiology, 2000:352. abstract.
- Nucci M, Santos LM, Ferradosa AS, Colombo AL. Epidemiology of candidemia due to C. parapsilosis in tertiary care hospitals in Brazil. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2001:393. abstract.
Cited by
Items 301–400 of 1,000
Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect
Wiederhold, N. P. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3282f1be7f · Cited by 65
Sepsis associated with immunosuppressive medications: An evidence-based review
Gea‐Banacloche, J., Opal, S. M., Jorgensen, J., Carcillo, J. A., Sepkowitz, K. A., & Cordonnier, C. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000143020.27340.ff · Cited by 69
Starzyk, J., Gruszecki, M., Tutaj, K., Luchowski, R., Szlązak, R., Waśko, P., Grudziński, W., Czub, J., & Gruszecki, W. I. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp510245n · Cited by 75
Mistry, G. C., Migoya, E., Deutsch, P. J., Winchell, G., Hesney, M., Li, S., Bi, S., Dilzer, S., Lasseter, K. C., & Stone, J. A. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007303764 · Cited by 66
Fungicidal versus Fungistatic: what's in a word?
Lewis, J. S., & Graybill, J. R. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.6.927 · Cited by 62
Tolerability profile of the current antifungal armoury
Mourad, A., & Perfect, J. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx446 · Cited by 62
Self-citationMicafungin: A New Echinocandin Antifungal
Joseph, J., Jain, R., & Danziger, L. H. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.1.53 · Cited by 69
Systemic Antifungal Therapy: New Options, New Challenges
Wong‐Beringer, A., & Kriengkauykiat, J. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.14.1441.31938 · Cited by 72
Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options
Ashley, E. D., Drew, R., Johnson, M., Danna, R., Dabrowski, D., Walker, V., Prasad, M., Alexander, B., Papadopoulos, G., & Perfect, J. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01124 · Cited by 62
Self-citationFungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
Improving the management of candidemia through antimicrobial stewardship interventions
Reed, E. E., West, J. E., Keating, E. A., Pancholi, P., Balada-Llasat, J.-M., Mangino, J. E., Bauer, K. A. A., & Goff, D. A. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.11.012 · Cited by 66
Majithiya, J., Sharp, A., Parmar, A., Denning, D. W., & Warn, P. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn431 · Cited by 62
Petraitienė, R., Petraitis, V., Hope, W. W., Mickiene, D., Kelaher, A. M., Murray, H. A., Mya-San, C., Hughes, J. E., Cotton, M. P., Bacher, J. D., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00674-08 · Cited by 66
Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes
Song, J. C., & Stevens, D. A. (2016) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1068271 · Cited by 61
Liu, N.-N., Flanagan, P. R., Zeng, J., Jani, N. M., Cardenas, M. E., Moran, G. P., & Köhler, J. R. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617799114 · Cited by 64
Nosocomial Candidemia: An Ounce of Prevention Is Better Than a Pound of Cure
Diekema, D. J., & Pfaller, M. A. (2004) · Infection Control and Hospital Epidemiology · doi:10.1086/502451 · Cited by 67
Kontoyiannis, D. P., & Lewis, R. E. (2003) · Drug Resistance Updates · doi:10.1016/j.drup.2003.08.003 · Cited by 67
Kabbara, N., Lacroix, C., Peffault de Latour, R., Socie, G., Ghannoum, M., & Ribaud, P. (2008) · Haematologica · doi:10.3324/haematol.11149 · Cited by 61
“Caspofungin is an effective treatment of candidiasis and has been shown to be as effective as amphotericin B for the treatment of candidemia whatever the species involved.(4) Recent reports on another echinocandin, micafungin, in the treatment of candidemia and invasive candidiasis showed an identical response among p…”
ResultFungal Infections in Transplant and Oncology Patients
Person, A. K., Kontoyiannis, D. P., & Alexander, B. D. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.01.002 · Cited by 61
Brito, L. R., Guimarães, T., Nucci, M., Rosas, R. C., Paula Almeida, L., Da Matta, D. A., & Colombo, A. L. (2006) · Medical Mycology · doi:10.1080/13693780500421476 · Cited by 61
Self-citationCaspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-10 · Cited by 60
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex
Barchiesi, F., Orsetti, E., Osimani, P., Catassi, C., Santelli, F., & Manso, E. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1704-y · Cited by 69
Low Caspofungin Exposure in Patients in Intensive Care Units
van der Elst, K. C. M., Veringa, A., Zijlstra, J. G., Beishuizen, A., Klont, R., Brummelhuis-Visser, P., Uges, D. R. A., Touw, D. J., Kosterink, J. G. W., van der Werf, T. S., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01582-16 · Cited by 64
Kartsonis, N. A. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh179 · Cited by 60
Self-citationMuthamil, S., Devi, V. A., Balasubramaniam, B., Balamurugan, K., & Pandian, S. K. (2018) · Journal of Basic Microbiology · doi:10.1002/jobm.201700529 · Cited by 66
EndogenousCandidaendophthalmitis
Sallam, A. B., Lynn, W. A., McCluskey, P., & Lightman, S. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.4.675 · Cited by 64
Tragiannidis, A., Dokos, C., Lehrnbecher, T., & Groll, A. H. (2012) · Drugs · doi:10.2165/11599810-000000000-00000 · Cited by 66
Steinbach, W. J. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.02.009 · Cited by 65
Topical Caspofungin for Treatment of Keratitis Caused by Candida albicans in a Rabbit Model
Goldblum, D., Frueh, B. E., Sarra, G., Κatsoulis, Κ., & Zimmerli, S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1359-1363.2005 · Cited by 65
Pelletier, R., Alarie, I., Lagacé, R., & Walsh, T. J. (2005) · Medical Mycology · doi:10.1080/13693780500220415 · Cited by 58
Dupont, B. F., Lortholary, O., Ostrosky-Zeichner, L., Stucker, F., & Yeldandi, V. (2009) · Critical Care · doi:10.1186/cc8117 · Cited by 58
Ruhnke, M., Paiva, J. A., Meersseman, W., Pachl, J., Grigoras, I., Sganga, G., Menichetti, F., Montravers, P., Auzinger, G., Dimopoulos, G., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03784.x · Cited by 58
Chemical inhibitors of Candida albicans hyphal morphogenesis target endocytosis
Bar-Yosef, H., Vivanco Gonzalez, N., Ben-Aroya, S., Kron, S. J., & Kornitzer, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-05741-y · Cited by 58
Vascular Catheter-Associated Infections: A Microbiological and Therapeutic Update
Viale, P., & Stefani, S. (2006) · Journal of Chemotherapy · doi:10.1179/joc.2006.18.3.235 · Cited by 66
Worth, L. J., Blyth, C. C., Booth, D., Kong, D. C. M., Marriott, D., Cassumbhoy, M., Ray, J. E., Slavin, M. A., & Wilkes, J. R. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01726.x · Cited by 63
Antifungal Therapy: Lessons Learned over the Past 27 Years
Dismukes, W. E. (2006) · Clinical Infectious Diseases · doi:10.1086/503043 · Cited by 64
Treatment of Candida Infections with Amphotericin B Lipid Complex
Ito, J. I., & Hooshmand-Rad, R. (2005) · Clinical Infectious Diseases · doi:10.1086/429330 · Cited by 58
Klastersky, J. A. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.11.002 · Cited by 64
Traditional and Emerging Antifungal Therapies
Arnold, T. M., Dotson, E. K., Sarosi, G. A., & Hage, C. A. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200906-048al · Cited by 69
Wiederhold, N. P., & Lewis, J. S. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1155 · Cited by 59
Arendrup, M. C., Rodriguez-Tudela, J.-L., Park, S., Garcia-Effron, G., Delmas, G., Cuenca-Estrella, M., Gomez-Lopez, A., & Perlin, D. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01364-10 · Cited by 57
“parapsilosis infections treated with echinocandins is comparable to that for infections with the other Candida species (19, 23, 27, 33), which may be due in part to C.”
ResultBiological Activities of Fungal Metabolites
Pel√°ez, F. (2004) · CRC Press eBooks · doi:10.1201/9780203970553-7 · Cited by 61
The echinocandins: three useful choices or three too many?
Bal, A. M. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.011 · Cited by 66
Pediatric Antifungal Utilization
Prasad, P. A., Coffin, S. E., Leckerman, K. H., Walsh, T. J., & Zaoutis, T. E. (2008) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31817eeee5 · Cited by 56
Persistence of Candida species in the respiratory tract of cystic fibrosis patients
Muthig, M., Hebestreit, A., Ziegler, U., Seidler, M., & Müller, F.-M. C. (2010) · Medical Mycology · doi:10.3109/13693780802716532 · Cited by 55
Concentration-Dependent Effects of Caspofungin on the Metabolic Activity of Aspergillus Species
Antachopoulos, C., Meletiadis, J., Sein, T., Roilides, E., & Walsh, T. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01160-06 · Cited by 56
Grudziński, W., Sagan, J., Welc, R., Luchowski, R., & Gruszecki, W. I. (2016) · Scientific Reports · doi:10.1038/srep32780 · Cited by 60
New antifungal agents under development in children and neonates
Steinbach, W. J., & Benjamin, D. K. (2005) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000185986.64759.9a · Cited by 59
Developments in the treatment of candidiasis: more choices and new challenges
Aperis, G., Myriounis, N., Spanakis, E. K., & Mylonakis, E. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.11.1319 · Cited by 56
Candida Prosthetic Valve Endocarditis Cured by Caspofungin Therapy without Valve Replacement
Rajendram, R., Alp, N. J., Mitchell, A. R. J., Bowler, I. C. J. W., & Forfar, J. C. (2005) · Clinical Infectious Diseases · doi:10.1086/429322 · Cited by 58
Waśko, P., Luchowski, R., Tutaj, K., Grudziński, W., Adamkiewicz, P., & Gruszecki, W. I. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300143n · Cited by 56
Atualização no uso de agentes antifúngicos
Martínez, R. (2006) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132006000500013 · Cited by 87
Rare and emerging Candida species
Johnson, E. M. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0020-z · Cited by 57
Diagnosis and Treatment of Candidemia in the Intensive Care Unit
Bassetti, M., Giacobbe, D. R., Vena, A., & Wolff, M. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1693704 · Cited by 72
Dong, P., Zong, C., Dagher, Z., Hui, J., Li, J., Zhan, Y., Zhang, M., Mansour, M. K., & Cheng, J. (2021) · Science Advances · doi:10.1126/sciadv.abd5230 · Cited by 60
Fujihara, N., Saito, T., Kudo, T., Iinuma, Y., Ichiyama, S., & Takakura, S. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1128-2 · Cited by 58
Blyth, C. C., Hale, K. A., Palasanthiran, P., O'Brien, T. A., & Bennett, M. H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006343.pub2 · Cited by 59
Cesaro, S., Toffolutti, T., Messina, C., Calore, E., Alaggio, R., Cusinato, R., Pillon, M., & Zanesco, L. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00254.x · Cited by 59
Attributable mortality of candidemia after introduction of echinocandins
Cornely, F. B., Cornely, O. A., Salmanton‐García, J., Koehler, F. C., Koehler, P., Seifert, H., Wingen‐Heimann, S., & Mellinghoff, S. C. (2020) · Mycoses · doi:10.1111/myc.13177 · Cited by 54
Nivoix, Y., Zamfir, A., Lutun, P., Kara, F., Remy, V., Lioure, B., RIGOLOT, J., Entz‐Werlé, N., Letscher‐Bru, V., Waller, J., et al. (2005) · Journal of Infection · doi:10.1016/j.jinf.2005.01.006 · Cited by 54
Candida Bloodstream Infections: Changes in Epidemiology and Increase in Drug Resistance
Kotey, F. C. N., Dayie, N. T. K. D., Tetteh‐Quarcoo, P. B., & Donkor, E. S. (2021) · Infectious Diseases Research and Treatment · doi:10.1177/11786337211026927 · Cited by 77
Karthaus, M. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-4-145 · Cited by 58
Invasive Fungal Infections in the ICU
Shoham, S., & Marwaha, S. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609355262 · Cited by 63
Development of Candidemia on Caspofungin Therapy: a Case Report
Cheung, C. N., Guo, Y., Gialanella, P., & Feldmesser, M. (2006) · Infection · doi:10.1007/s15010-006-5613-7 · Cited by 56
Invasive candidiasis in cancer patients: observations from a randomized clinical trial
DiNubile, M. J., Hille, D. A., Sable, C. A., & Kartsonis, N. A. (2005) · Journal of Infection · doi:10.1016/j.jinf.2005.01.016 · Cited by 57
Self-citationDignan, F. L., Evans, S. O., Ethell, M. E., Shaw, B. E., Davies, F. E., Dearden, C. E., Treleaven, J. G., Riley, U., Morgan, G. J., & Potter, M. N. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.427 · Cited by 52
the study group Candida albicans Germ Tube Antibody Detection in Critically Ill Patients (CAGTAUCI), Pemán, J., Zaragoza, R., Quindós, G., Alkorta, M., Cuétara, M. S., Camarena, J. J., Ramírez, P., Giménez, M. J., Martín‐Mazuelos, E., et al. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-60 · Cited by 55
Rosa, F. G. D., Corcione, S., Filippini, C., Raviolo, S., Fossati, L., Montrucchio, C., Aldieri, C., Petrolo, A., Cavallo, R., & Perri, G. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125149 · Cited by 56
Surgical critical care: Fungal infections in surgical patients
Lipsett, P. A. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000231883.93001.e0 · Cited by 52
Begier, E. M., Oberste, M. S., Landry, M. L., Brennan, T. P., Mlynarski, D., Mshar, P., Frenette, K., Rabatsky‐Ehr, T., Purviance, K., Nepaul, A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590562 · Cited by 54
Current therapeutic approaches to fungal infections in immunocompromised hematological patients
Pagano, L., Caira, M., Valentini, C. G., Posteraro, B., & Fianchi, L. (2010) · Blood Reviews · doi:10.1016/j.blre.2009.11.003 · Cited by 54
Antifungal Activity of Baicalein Against Candida krusei Does Not Involve Apoptosis
Kang, K., Fong, W., & Tsang, P. W. (2010) · Mycopathologia · doi:10.1007/s11046-010-9341-2 · Cited by 56
Wiederhold, N. P., Grabinski, J. L., Garcia-Effron, G., Perlin, D. S., & Lee, S. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00959-08 · Cited by 52
López-Ciudad, V., Castro-Orjales, M. J., León, C., Sanz-Rodríguez, C., de la Torre-Fernández, M. J., de Juan-Romero, M. A. P., Collell-Llach, M. D., & Díaz-López, M. D. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-73 · Cited by 52
Slavin, M. A., Szer, J., Grigg, A., Roberts, A. W., Seymour, J. F., Sasadeusz, J., Thursky, K., Chen, S. C., Morrissey, C. O., Heath, C. H., et al. (2004) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2004.00541.x · Cited by 51
Role of Antifungal Combinations in Difficult to Treat Candida Infections
Vitale, R. G. (2021) · Journal of Fungi · doi:10.3390/jof7090731 · Cited by 52
Candida glabrata – unique features and challenges in the clinical management of invasive infections
Glöckner, A., & Cornely, O. A. (2015) · Mycoses · doi:10.1111/myc.12348 · Cited by 49
Lestner, J. M., Smith, P. B., Cohen‐Wolkowiez, M., Benjamin, D. K., & Hope, W. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12025 · Cited by 50
New developments and directions in the clinical application of the echinocandins
Chang, C. C., Slavin, M. A., & Chen, S. C. A. (2017) · Archives of Toxicology · doi:10.1007/s00204-016-1916-3 · Cited by 56
Disposition of Caspofungin, a Novel Antifungal Agent, in Mice, Rats, Rabbits, and Monkeys
Sandhu, P., Xu, X., Bondiskey, P. J., Balani, S. K., Morris, M. L., Tang, Y. S., Miller, A. R., & Pearson, P. G. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1272-1280.2004 · Cited by 49
Emerging echinocandins for treatment of invasive fungal infections
Turner, M. S., Drew, R. H., & Perfect, J. R. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.2.231 · Cited by 49
Self-citationHoward, S. J., Livermore, J., Sharp, A., Goodwin, J., Gregson, L., Alastruey-Izquierdo, A., Perlin, D. S., Warn, P. A., & Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00621-11 · Cited by 48
DeJarnette, C. A., Luna-Tapia, A., Estredge, L. R., & Palmer, G. E. (2020) · mSphere · doi:10.1128/msphere.00374-20 · Cited by 54
Rahi, M. S., Jindal, V., Pednekar, P., Parekh, J., Gunasekaran, K., Sharma, S., Stender, M., & Jaiyesimi, I. A. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211039050 · Cited by 63
Paradoxical echinocandin activity: a limited in vitro phenomenon?
Wiederhold, N. P. (2009) · Medical Mycology · doi:10.1080/13693780802428542 · Cited by 48
Chiotos, K., Vendetti, N., Zaoutis, T. E., Baddley, J., Ostrosky-Zeichner, L., Pappas, P., & Fisher, B. T. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw305 · Cited by 48
Recent Advances in Antifungal Prevention and Treatment
Groll, A. H., & Tragiannidis, A. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.03.003 · Cited by 51
A comparative evaluation of properties and clinical efficacy of the echinocandins
Kim, R., Khachikian, D., & Reboli, A. C. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.10.1479 · Cited by 50
Würthwein, G., Young, C., Lanvers‐Kaminsky, C., Hempel, G., Trame, M. N., Schwerdtfeger, R., Ostermann, H., Heinz, W., Cornely, O. A., Kolve, H., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00265-11 · Cited by 52
Prabhu, R. M., & Orenstein, R. (2004) · Clinical Infectious Diseases · doi:10.1086/424449 · Cited by 47
Fungal infections in lung transplant recipients
Silveira, F. P., & Husain, S. (2008) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3282f9b1d1 · Cited by 47
Glöckner, A. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-4-167 · Cited by 52
Ko, J., Jung, D. S., Lee, J. Y., Kim, H. A., Ryu, S. Y., Jung, S., Joo, E., Cheon, S., Ys, K., Kim, S., et al. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2019.05.017 · Cited by 46
Song, Y., Chen, X., Yan, Y., Wan, Z., Liu, W., & Li, R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01401 · Cited by 46
Ocular penetration of caspofungin in a rabbit uveitis model
Goldblum, D., Fausch, K., Frueh, B. E., Theurillat, R., Thormann, W., & Zimmerli, S. (2006) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-006-0460-x · Cited by 48
DiNubile, M. J., Lupinacci, R. J., Strohmaier, K. M., Sable, C. A., & Kartsonis, N. A. (2007) · Journal of Critical Care · doi:10.1016/j.jcrc.2006.11.004 · Cited by 46
Self-citationMetcalf, S. C., & Dockrell, D. H. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.06.012 · Cited by 52
Amran, F. B., Aziz, M. N., Ibrahim, H. M., Atiqah, N. H., Parameswari, S., Hafiza, M. R., & Ifwat, M. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.027631-0 · Cited by 51
Echinocandins: role in antifungal therapy, 2005
Zaas, A. K., & Alexander, B. D. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.10.1657 · Cited by 43
Prophylaxis and treatment of invasive candidiasis in the intensive care setting
Ostrosky-Zeichner, L. L. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1215-4 · Cited by 48
Metadata
- Authors
- Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J.
- Affiliations
- Costa Rican Department of Social Security (CR)
- University of Rochester (US)
- McMaster University (CA)
- Universidade Federal de São Paulo (BR)
- Clinica Santa Maria (CL)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-12-19
- Volume
- 347
- Issue
- 25
- Pages
- 2020-2029
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003661565
- Cited by
- 1,380
- References
- 31
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 17 · 2023: 14 · 2022: 18 · 2021: 30 · 2020: 28 · 2019: 30 · 2018: 29 · 2017: 44 · 2016: 30 · 2015: 50 · 2014: 44 · 2013: 53 · 2012: 62
- FWCI
- 56.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, amphotericin B deoxycholate, invasive candidiasis, candidemia, echinocandins, antifungal therapy, treatment efficacy, drug-related adverse events, neutropenia, APACHE II score, Candida species, randomized trial comparison, length of hospital stay, cost-effectiveness
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candida, Candidiasis, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Peptides, Peptides, Cyclic, Recurrence, Fungemia, APACHE, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.